Article Information
History
- March 29, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Francesca Ammoscato1,
- Mohammad Aboulwafa1,3,
- Justyna Skonieczna1,
- Jonathan Bestwick2,
- Rosemary Monero4,
- Michael Andrews3,
- Stefania De Trane1,5,
- David Holden1,
- Ashok Adams3,
- Lucia Bianchi1,
- Ben Turner3,
- Monica Marta3,
- Klaus Schmierer1,3,
- David Baker1,
- Gavin Giovannoni1,3 and
- Sharmilee Gnanapavan3,*
- 1Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 2Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, UK
- 3Department of Neurology, Royal London Hospital, London, UK
- 4Department of Neuroimmunology, Institute of Neurology, Queen Square, London UK
- 5Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Bari Institute, Italy
- ↵*Corresponding author: Dr S Gnanapavan MD PhD, Department of Neurology, The Royal London Hospital, Barts Health NHS Trust, London E1 2AA, Email: sharmilee.gnanapavan{at}nhs.net
Posted March 29, 2024.
Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells
